1	Temporal changes in the positivity rate of common enteric viruses among paediatric admissions in
2	coastal Kenya, in the period spanning the COVID-19 pandemic, 2019-2022
3 4	Authors:
5	Arnold W. Lambisia ^{1, *} , Nickson Murunga ¹ , Martin Mutunga ¹ , Robinson Cheruiyot ¹ , Grace
6	Maina ¹ , Timothy O. Makori ¹ , D. James Nokes ^{1,2} , Charles N. Agoti ^{1,3}
7	
8	Author Affiliations:
9	¹ Kenya Medical Research Institute-Wellcome Trust Research Programme (KWTRP), P.O Box
10	230-80108 Kilifi, Kenya.
11	² School of Life Sciences and Zeeman Institute for Systems Biology and Infectious Disease
12	Epidemiology Research (SBIDER), University of Warwick, CV4 7AL Coventry, United Kingdom.
13	³ Department of Public Health, Pwani University, Kilifi P.O. Box 195-80108, Kenya.
14 15	*Corresponding author:
16	Contact details: P.O. Box 230, Kilifi-80108, Kenya,
17	Email: alambisia@kemri-wellcome.org
18	
19	Key words: Enteric viruses, COVID-19, Rotavirus A, positivity rate, Kenya, paediatrics

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

21 Background

The non-pharmaceutical interventions (NPIs) implemented to curb the spread of SARS-CoV-2 early in the COVID-19 pandemic years, disrupted the activity of other respiratory viruses. There is limited data from low-and-middle income countries (LMICs) to determine whether COVID-19 NPIs also impacted the epidemiology of enteric viruses. We investigated the changes in infection patterns of common enteric viruses among hospitalised children who presented with diarrhoea to a referral hospital in coastal Kenya, in the period spanning the COVID-19 pandemic.

29

30 Methods

A total of 870 stool samples from children under 13 years of age admitted to Kilifi County Hospital between January 2019, and December 2022 were screened for rotavirus group A (RVA), norovirus genogroup II (GII), astrovirus, sapovirus, and adenovirus type F40/41 using real-time reverse-transcription polymerase chain reaction. The proportions positive across the four years were compared using the chi-squared test statistic.

36

37 Results

38 One or more of the five virus targets were detected in 282 (32.4%) cases. A reduction in the positivity rate of RVA cases was observed from 2019 (12.1%, 95% confidence interval (CI) 8.7% 39 40 -16.2%) to 2020 (1.7%, 95% CI 0.2% – 6.0%; p < 0.001). However, in the 2022, RVA positivity rate rebounded to 23.5% (95% CI 18.2% - 29.4%). For norovirus GII, the positivity rate 41 42 fluctuated over the four years with its highest positivity rate observed in 2020 (16.2%; 95% 43 C.I, 10.0% – 24.1%). No astrovirus cases were detected in 2020 and 2021, but the positivity rate in 2022 was similar to that in 2019 (3.1% (95% CI 1.5% - 5.7%) vs 3.3% (95% CI 1.4% -44 45 6.5%)). A higher case fatality rate was observed in 2021 (9.0%) compared to the 2019 (3.2%), 46 2020 (6.8%) and 2022 (2.1%) (*p* < 0.001).

47

48 Conclusion

Our study finds that in 2020 the transmission of common enteric viruses, especially RVA and
astrovirus, in Kilifi Kenya may have been disrupted due to the COVID-19 NPIs. After 2020, local

- 51 enteric virus transmission patterns appeared to return to pre-pandemic levels coinciding with
- 52 the removal of most of the government COVID-19 NPIs.

53 Introduction

Although water sanitation and hygiene (WASH) programmes and new vaccine introductions have resulted in significant reductions of paediatric diarrhoea morbidity and mortality globally, virus-associated diarrhoea is still a major cause of hospital admissions in several low and middle-income settings ¹. In 2019, approximately 300,000 deaths were recorded globally in children below 14 years of age due to rotavirus group A (RVA), norovirus GI and GII, and adenovirus 40/41 infections ².

60

Following the emergence of COVID-19, a number of reports have indicated perturbations in 61 62 in seasonality, prevalence and incidence of common enteric viruses associated with diarrhoea disease. For instance, in France ³, Poland ⁴, China ^{5,6} and USA ⁷, the prevalence of RVA during 63 64 the year 2020 was lower compared to 2018 and 2019. However, in 2021 there was a surge of RVA cases in these countries. Like RVA, a decrease in cases of norovirus GII, sapovirus, 65 adenovirus 40/41 and astrovirus was reported in 2020 in Spain⁸ and Korea⁹ compared to 66 67 previous years. However, this decrease in virus detection has been followed by remarkable 68 outbreaks in 2021 ^{5,10}. Sporadic outbreaks of norovirus have also been reported in China in 69 September 2020 and in the USA, where a total of 992 norovirus outbreaks were reported 70 between August 2021 and July 2022 ^{5,11,12}. The decline of the detection rates of enteric viruses 71 in the early COVID-19 pandemic phase has been postulated to be a result of the stringent non-72 pharmaceutical interventions (NPIs) that were implemented to abrogate the pandemic ¹³. Some of the measures included those that may impact enteric pathogen transmission such as 73 74 frequent hand washing, increased hygiene, social distancing, closure of restaurants and 75 restricted movement either locally or internationally ¹³.

76

In coastal Kenya, the prevalence of enteric viruses over the past decade has been monitored and no significant change in the prevalence has been detected in all the viruses except for sapovirus (7.6% vs 4.0%, *p value* <0.05) pre-post rotavirus vaccine introduction in July 2014 ¹⁴. RVA positivity in hospital admissions decreased significantly only among ELISA detected cases but not RT-PCR detected cases ¹⁵. Continuous monitoring of these enteric viruses that commonly cause diarrhoea in childhood is key in providing insights on their epidemiology for disease management and informing public health policy. In this study, we aimed to describe

84	the epidemiological patterns of common enteric viruses associated with diarrhoea between
85	January 2019 and December 2022, during a period spanning the COVID-19 pandemic.
86	

87 Methods

88 Study site and population

This study was undertaken as part of our routine surveillance of RVA in Kilifi County Hospital
(KCH), Kenya ^{14,16,17}. To be recruited, a participant had to satisfy the following criteria: (a)
admitted with diarrhoea as one of their illness symptom(s), (b) aged < 13-year-old, (c) consent
given from a parent or guardian to be in the study ^{14,16,17} The surveillance started in 2009 and
has continued to date (2023). In this analysis we focused on participants recruited between
1st January 2019 and 31st December 2022.
Laboratory methods.

97 Molecular testing for common enteric viruses

98 Total Nucleic Acid (TNA) Extraction

99 TNA was extracted from 0.2 grams of stool (or 200ul if liquid) using the QIAamp Fast DNA Stool

- Mini kit (Qiagen, Manchester, UK) and eluted in 200ul of elution buffer as previously described
 ^{14,16}.
- 102

103 Virus (RT)-PCR Screening

104 The extracted TNA was combined with the TaqMan Fast Virus 1-step master mix and virus 105 specific primers (**supplementary table 1**) for each of the five viruses ^{16,18} and processed on a 106 real-time Quantistudio 5-flex instrument. The reaction mix comprised 2.5µl of the TaqMan 107 master mix, 1.2µl of the primer-probe mix, 3.8µl of nuclease free water and 5µl of TNA. The 108 thermocycling conditions were as follows; 95°C for 20 sec and 35 cycles of 94°C for 15 sec and 109 60°C for 30 sec. A cycle threshold cut-off of < 35.0 was applied to determine virus positive 110 samples for all targets screened.

111

112 **RVA genotyping**

113 TNA from RVA positives were amplified using segment specific primers, sequenced on the 114 Illumina Miseq platform as previously described ¹⁹. Genomes were assembled from the short

read data using a de novo assembly approach as previously described ¹⁹. RVA genotypes were
 assigned using either BLAST or an online RVA genotyping tool ²⁰.

117

118 Statistical Analysis

All statistical analysis was undertaken using R version 4.1.1 (2021-08-10). The level of government intervention was summarised using the Oxford Stringency index (SI), a composite measure based on nine response indicators including school closures, workplace closures, and travel bans, rescaled to a value from 0 to 100 (100 = strictest) ²¹. Local stringency measures have been highlighted elsewhere ²² and summarized in supplementary table 2.

The virus positivity rate during each year was calculated as the proportion of samples that tested positive for the given virus given the total number of samples tested in the defined year. The data from 2019 has been previously published elsewhere and formed a reference base of the situation before COVID-19¹⁶. Comparisons across different years and groups were done using the chi-squared test statistic. Kruskal Wallis and Wilcoxon rank-sum tests were used to compare the distribution of continuous variables. Disease severity was estimated using the Vesikari Clinical Severity Scoring System Manual as previously described ^{16,23}.

132 Results

133 Basic demographic characteristics

Between January 2019 and December 2022, 1,613 patients aged under 13 years presented with diarrhoea as one of their illness symptoms at KCH. Of these, 870 (54.0%) consented enrolment into the study, gave a stool sample, and were included in this analysis. The reasons for missed sample collection in the study were: consent refusal (n=344), other (n=133), death (n=68), discharged before sample collection(n=35) and transferred before sample collection (n=3).

- 141 All the 870 stool samples were screened for the five enteric viruses namely, RVA, norovirus
- 142 GII, astrovirus, sapovirus and adenovirus F40/41. The majority of the recruited patients were
- in their first year of life (n=371, 42.6%) and all suffered moderate-to-severe diarrhoeal disease
- 144 (**Table 1**). The characteristics of the observed cases across the four years in terms of gender
- and age were similar (*p value > 0.05*). However, fatal outcome appeared more likely to occur
- in 2021 (9.0%) compared to 2019 (3.2%), 2020 (6.8%) and 2022 (2.1%) (*p* value < 0.001, **Table**
- 147 **1**). Less severe disease was also reported in 2020 compared to the other three years, **Table 1**.

148 **Table 1:** Demographic characteristics of children under 13 years admitted to Kilifi County

149

Hospital, Kenya between January 2019 and December 2022

	2019	2020	2021	2022	Total	B value
	(n=314) *	(n=117)	(n=201)	(n=238)	(n=870)	r value
Sex						0.586
Female	137 (43.6%)	45 (38.5%)	81 (40.3%)	107 (45.0%)	370 (42.5%)	
Male	177 (56.4%)	72 (61.5%)	120 (59.7%)	131 (55.0%)	500 (57.5%)	
Median age in months (Interquartile range)	14.0 (8.0 – 25.0)	13.7 (8.1 – 27.0)	13.0 (7.5 – 23.4)	13.2 (8.5 – 21.3)	13.7 (8.1 – 23.0)	
Age strata (months)						0.252
<12	128 (40.8%)	51 (43.6%)	89 (44.3%)	103 (43.3%)	371 (42.6%)	
12 -23	102 (32.5%)	36 (30.8%)	64 (31.8%)	86 (36.1%)	288 (33.1%)	
24 -59	56 (17.8%)	13 (11.1%)	33 (16.4%)	35 (14.7%)	137 (15.7%)	
>60	28 (8.9%)	17 (14.5%)	15 (7.5%)	14 (5.9%)	74 (8.5%)	
Outcome						<0.001
Alive	276 (87.9%)	109 (93.2%)	183 (91.0%)	231 (97.1%)	799 (91.8%)	
Dead	10 (3.2%)	8 (6.8%)	18 (9.0%)	5 (2.1%)	41 (4.7%)	
Data missing	28 (8.9%)	0 (0.0%)	0 (0.0%)	2 (0.8%)	30 (3.4%)	
Disease severity						0.01
Moderate	90 (28.7%)	47 (40.2%)	45 (22.4%)	65 (27.3%)	247 (28.4%)	
Severe	224 (71.3%)	70 (59.8%)	156 (77.6%)	173 (72.7%)	623 (71.6%)	
*Pre-pandemic data has been reported in an earlier manuscript ¹⁶						

150

151 Trends in diarrhoeal cases in the context of the COVID-19 pandemic

After the initial detection of the first COVID-19 case in Kenya on 12th March 2020 ²⁴, the government implemented a range of NPIs to curb the pandemic (summarised in Figure 1a using the Oxford Stringency index and local restrictions listed in supplementary table 2). The trend of monthly recorded diarrhoea cases recruited into our surveillance between January 2019 and December 2022 is shown in **Figure 1b.** The highest monthly peak in cases was recorded in 2019 before the COVID-19 pandemic. The lowest number of diarrhoea cases was in the 2020, but a gradual rebound was observed in 2021 and 2022.



160

Figure 1: A) COVID-19 stringency index quantifying the government NPI measures aimed to
curb the spread of SARS-CoV-2 (source: https://ourworldindata.org/covid-stringency-index).
B) Temporal trends of monthly diarrhoea and virus cases between January 2019 and
December 2022. The blue and red line graphs show the total eligible and recruited diarrhoea
cases respectively, while the bar graphs show the total virus positive cases per month.

166

167 Single virus infections and coinfections

At least one of the five virus targets were detected in 282 (32.4%) cases. The proportion of samples positive for the five viruses we tested in the stool samples for the different years is summarised in table 1. The positivity rate of RVA deeped in 2020, at 1.7% (95% C.I, 0.2% – 6.0%) compared to 2019 (12.1% (95% C.I, 8.7%-14.9%) and gradually rose in 2021 (16.9% (95% C.I, 12.0% - 22.8%)) and 2022 (23.5% (95% C.I, 18.2% - 29.4%)) and the differences were statistically significant (p value < 0.001) **(Table 2).**

174

175 The norovirus GII positivity rate fluctuated over the four years and the difference was 176 statistically significant (p value 0.04) **(Table 2).** The highest positivity rate for norovirus GII was

- 177 16.2% (95% C.I, 10.0% 24.1%) in 2020 and lowest at 6.4% (95% C.I, 3.4% 10.8%) in 2021
- 178 (Table 2). No astrovirus cases were detected in the 2020 and 2021, but the cases in 2022
- 179 (3.3%) with a similar positivity rate to what was reported in 2019 (3.1%, **Table 2**). The positivity
- 180 rates for sapovirus and adenovirus type F40/41 did not change across the three phases (p
- 181 *value* > 0.05, χ2).
- 182
- **Table 2:** Comparison of the detection rates of five common enteric virus between January
- 184 2019 and December 2022

	Total (n=870) 2		(n=314)	2020 (n=117)		2021 (n=201)		2022 (n=238)		Р
										value
		Cases	Proportion	Cases	Proportion	Cases	Proportion	Cases	Proportio	
			(95% CI)		(95% CI)		(95% CI)		n (95% Cl)	
Virus										
Rotavirus	130 (14.9%)	38	12.1 (8.7 -	2	1.7 (0.2 –	34	16.9 (12.0	56	23.5 (18.2	<0.00
			16.2)		6.0)		- 22.8)		- 29.4)	1
Norovirus	89 (10.2%)	34	10.8 (7.6 –	19	16.2 (10.0	13	6.4 (3.4 -	23	9.6 (6.2 –	0.04
GII			14.8)		- 24.1)		10.8)		14.1)	
Astrovirus	18 (2.1%)	10	3.1 (1.5 –	0	-	0	-	8	3.3 (1.4 –	0.01
			5.7)						6.5)	
Sapovirus	33 (3.8%)	11	3.5 (1.7 –	3	2.5 (0.5 –	7	3.4 (1.4 –	12	5.0 (2.6 –	0.65
			6.1)		7.3)		7.0)		8.6)	
Adenovirus	30 (3.4%)	9	2.8 (1.3–	8	6.8 (2.9 -	6	2.9 (1.1 –	7	2.9 (1.1 –	0.19
F40/41			5.3)		13.0)		6.3)		5.9)	

185

186 Between 2019 and 2022, 13 samples had a coinfection of two or more viruses of the screened

187 viruses. The most common coinfections were RVA and norovirus GII (n=4), adenovirus 40/41

and astrovirus (n=3), and adenovirus 40/41 and sapovirus (n=3) (**Supplementary table 3**).

189

190 Monthly virus trends

- In all the years, peak RVA cases were observed in the month of August, except in 2020 where only two RVA cases were detected, **Figure 2.** The peak months for norovirus GII varied across the different years. Less than five cases were reported over the four years for adenovirus 40/41, sapovirus and astrovirus in each month. In 2020 and 2021, no astrovirus cases were detected but re-emerged in 2022 (**Figure 2**).
- 196



199

200 Figure 2: Monthly temporal distribution of common enteric virus cases in children under 13 201 years admitted to KCH with diarrhoea between January 2019 and December 2022. The black 202 trendline shows the monthly diarrhoeal cases over time and the vertical dotted line represents 203 when the first COVID-19 case was detected in Kenya.

204

205

RVA genotypes and vaccination status of positive cases 206

207 Of the 130 RVA positive detected during the study, 87 (66.9%) and 70 (53.8%) successively 208 sequenced in the VP7 and VP4 segment, respectively. The years 2019, 2020 and 2021 were 209 predominated by the G3P[8] genotype (n=48, 80.0%). In 2022, we observed replacement of 210 the G3P[8] genotype with multiple genotypes: G2P[4] (n=2), G9P[8] (n=10), and G9P[4] (n=4). 211 To note, in the 2022 there was some incomplete genotyping due to failed sequencing in the 212 VP4 and VP7 segments G2P[x] (n=5) and GxP[8] (n=8), Among the 130 RVA positive cases, 88

- 213 (67.7%) had received at least one dose of the Rotarix[®] vaccine two doses, 18 (12.9%) had not
- received a vaccine and 24 (16.9%) had no vaccination records. One participant was RVA
- 215 positive five days after receiving a Rotarix dose and their sample genotyped as G3P[8].
- 216
- 217

218 Disease outcome

- In the study, a total of 41 (4.7%) cases succumbed among the 870 that we analysed. Only nine
- of these cases were positive for at least of the viruses we tested i.e., norovirus GII (n=4),
- adenovirus type F40/41 (n=2), RVA (n=1), sapovirus (n=1) and a coinfection (RVA & sapovirus,
- n=1) (Supplementary Figure 2). The other 32 cases had none of the five viruses detected.

223 Discussion

In this coastal Kenya hospital-based study, we observed a decrease in paediatric diarrhoea 224 225 admissions in during the first year of the COVID-19 pandemic (2020) compared to the pre-226 pandemic year (2019). This decline may be attributed in part to be a result of the 227 implementation of NPIs such as restriction of movement and increased hygiene practices that may have led to reduce transmission of the enteric pathogens as observed elsewhere ⁸ and 228 229 the overall reduced access to the hospital occasioned by health worker strike between 230 December 2020. Peak diarrhoea cases are usually observed between June and July and in 231 2020 and 2021, this period coincided with high stringency measures in the country. After 232 March 2021, targeted vaccination campaigns started replacing NPIs and from August 2021, 233 the government dropped measures including closure of schools, curfews, lockdowns and 234 public gatherings and restrictions in public transport.

235

We report a significant decrease in RVA positivity rate in 2020 compared to 2019 followed by a rebound in 2021 and 2022, a finding consistent with other studies elsewhere ^{4,6–8}. Notably, the positivity rate of RVA in 2022 was higher compared to all the previous years. Such a resurgence of RVA activity was also observed in Hong Kong after the first year of the pandemic⁵.

241

The return and increase of RVA activity in the 2021 and 2022 can be attributed in part to the 242 243 relaxation of the COVID-19 NPIs or circulation of strains heterologous to the Rotarix vaccine (e.g. G9P[8], G9P[4] and G2P[4]). Some of these strains have been noted to have limited cross-244 245 reactivity with the Rotarix G1P[8] strain. Further, vaccination delays and Rotarix[®] vaccine 246 stockouts that occurred in between June 2022 and January 2023 when a vaccine switch to Rotavac was made in Kenya²⁵. The introduction of G9 genotypes in Malaysia was associated 247 with an increase RVA prevalence ²⁶ similar to what we observed in 2022 whereby the G3P[8] 248 249 were rapidly replaced by the G9P[8], G9P[4] and G2P[4] genotypes and subsequently there 250 was an increase in RVA cases.

251

In Kilifi, the prevalence of norovirus GII has been on the rise post-rotavirus vaccine introduction compared to the pre-vaccine period ^{14,16}. Interestingly, the positivity rate of norovirus GII was highest in 2020 phase compared to other years. This implies that norovirus

activity was less impacted by the NPI measures which is known to be highly infectious. An increase in norovirus activity and multiple sporadic outbreaks have reported in the USA and China during the COVID-19 phase ^{5,11,12}.

258

Notably, astrovirus was not detected in the 2020 and 2021 but re-emerged in the 2022 with a positivity rate similar to what was observed in 2019. Astrovirus and sapovirus detection on the Kenyan coast has been always characterised by very low prevalence (<5%) ^{14,16}.

262

263 In China, enteric virus coinfections especially with RVA and norovirus was associated with 264 severe disease ²⁷. Similarly in coastal Kenya, a coinfection with either RVA or/and norovirus 265 GII coincided with severe disease. However, its key to note that 71.6% of the participants in 266 the study presented with severe disease. In 2020, there was a significant difference in 267 mortality rate (9.0%) compared to the 2019 (3.2%), 2021 (6.8%) and 2022 (2.1). We 268 hypothesize that the high mortality rate in the 2020 and partly 2021 may have been caused 269 by the challenges with access to the hospitals and health care services as efforts were geared 270 towards management of COVID-19 cases.

271

This study had several limitations. We did not analyse healthy controls from the same population to adjust the aetiological fraction for asymptomatic carriage in the population. With the small number of detections for some of the virus targets, it hard to confidently infer seasonality without a larger study. There was substantial data missingness e.g., on deaths and almost half of the eligible participants refused consent to be in the study. For a conclusive inference of changes of the incidence of these viruses before during and after the pandemic, a population-based study with a clear population-based denominator is necessary.

279

In conclusion, our study observed a decrease in total diarrhoea admissions and enteric virus activity during in 2020 and 2021. However, in 2022 an increase in RVA and astrovirus activity is restored to pre-pandemic numbers. Therefore, continuous enteric virus surveillance is key in understanding the temporal changes in positivity rate of these viruses to inform public health policy.

285

287 Declarations

- 288 Ethics approval and consent to participate.
- 289 The research protocol for the study was approved at Kenya Medical Research Institute
- 290 (KEMRI), by the Scientific and Ethics Review Unit (SSC#2861) in Nairobi, Kenya.

291 Acknowledgement

- 292 We are grateful to the study participants who provided samples and members of the
- 293 pathogen epidemiology and omics group at KEMRI-Wellcome Trust Programme who did
- 294 sample collection and laboratory processing. This manuscript was written with the
- 295 permission of Director KEMRI CGMRC

296 **Funding.**

- This study was funded by the Wellcome Trust (102975, 220985 and 226002/Z/22/Z). Dr
- 298 Charles Agoti was supported by the Initiative to Develop African Research Leaders (IDeAL)
- through the DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an
- 300 independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for
- 301 Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for
- 302 Africa's Development Planning and Coordinating Agency (NEPAD Agency). The views
- 303 expressed in this report are those of the authors and not necessarily those of AAS, NEPAD
- 304 Agency and The Wellcome. This research was funded in whole or in part by the Wellcome
- Trust [102975, 220985 and 226002/Z/22/Z], For the purpose of Open Access, the author has
- 306 applied a CC-BY public copyright license to any author accepted manuscript version arising
- 307 from this submission.
- 308 **Consent for publication**
- 309 Yes.
- 310 Competing interests
- 311 The authors declare no conflict of interest.
- 312 Availability of data and materials
- 313 All the data used can be accessed at the KWTRP Research repository via
- 314 https://doi.org/10.7910/DVN/EG6MEH.
- 315 Authors' contributions
- CAN and DJN sourced the study funding. CNA, DJN and AWL designed the study laboratory
- 317 assay. AWL, MM, TOM, CR, and GM did the laboratory experiments. NM and AWL managed

- 318 the study data and did the data analysis. AWL and CAN wrote the first manuscript draft. All
- authors read, revised, and approved the final manuscript.

320 References

321	1.	Reiner RC, Wiens KE, Deshpande A, Baumann MM, Lindstedt PA, Blacker BF, et al.
322		Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in
323		low-income and middle-income countries, 2000–17: analysis for the Global Burden of
324		Disease Study 2017. Lancet [Internet]. 2020 Jun;395(10239):1779–801. Available
325		from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620301148
326	2.	Institute for Health Metrics and Evaluation I. Default results are global all-cause
327		deaths and DALYs for 2019 with trends since 1990 [Internet]. 2022 [cited 2022 Sep
328		27]. Available from: https://vizhub.healthdata.org/gbd-results/
329	3.	Cohen PR, Rybak A, Werner A, Béchet S, Desandes R, Hassid F, et al. Trends in
330		pediatric ambulatory community acquired infections before and during COVID-19
331		pandemic: A prospective multicentric surveillance study in France. Lancet Reg Heal -
332		Eur. 2022;22:1–10.
333	4.	Toczylowski K, Jackowska K, Lewandowski D, Kurylonek S, Waszkiewicz-Stojda M,
334		Sulik A. Rotavirus gastroenteritis in children hospitalized in northeastern Poland in
335		2006–2020: Severity, seasonal trends, and impact of immunization. Int J Infect Dis
336		[Internet]. 2021;108:550–6. Available from:
337		https://doi.org/10.1016/j.ijid.2021.05.070
338	5.	Chan MCW. Return of Norovirus and Rotavirus Activity in Winter 2020–21 in City with
339		Strict COVID-19 Control Strategy, China. Emerg Infect Dis [Internet]. 2022
340		Mar;28(3):713–6. Available from: https://wwwnc.cdc.gov/eid/article/28/3/21-
341		2117_article.htm
342	6.	Fang C, Zhou Z, Li J, Zhou M. Incident changes of rotavirus enteritis among children
343		during the coronavirus disease-2019 pandemic in Hangzhou, China. J Infect [Internet].
344		2022 Jan;84(1):e9–10. Available from: https://doi.org/10.1016/j.jinf.2021.09.007
345	7.	Burnett E, Parashar UD, Winn A, Tate JE. Trends in Rotavirus Laboratory Detections
346		and Internet Search Volume Before and After Rotavirus Vaccine Introduction and in
347		the Context of the Coronavirus Disease 2019 Pandemic-United States, 2000-2021. J
348		Infect Dis [Internet]. 2022 Sep 21;226(6):967–74. Available from:
349		http://www.ncbi.nlm.nih.gov/pubmed/35184198
350	8.	Maldonado-Barrueco A, García-Rodríguez J, Yániz-Ramirez J, Serrano-Vaquero I,

351 Parra-Alonso JC, Vega-Nieto C, et al. Impact of the SARS-CoV-2 Pandemic on the

352		Prevalence and Incidence of Gastrointestinal Viruses in Children up to Five Years Old:
353		a Retrospective Cohort Study. Microbiol Spectr. 2022;10(3).
354	9.	Ahn SY, Park JY, Lim IS, Chae SA, Yun SW, Lee NM, et al. Changes in the Occurrence of
355		Gastrointestinal Infections after COVID-19 in Korea. J Korean Med Sci. 2021;36(24):1-
356		9.
357	10.	Douglas A, Sandmann FG, Allen DJ, Celma CC, Beard S, Larkin L. Impact of COVID-19
358		on national surveillance of norovirus in England and potential risk of increased
359		disease activity in 2021. J Hosp Infect. 2021;112:124–6.
360	11.	Kambhampati AK, Wikswo ME, Barclay L, Vinjé J, Mirza SA. Norovirus Outbreaks
361		Reported Through NoroSTAT — 12 States, August 2012–July 2022. MMWR Recomm
362		Reports. 2022;71(38):1222–4.
363	12.	Lu Y, Zhang Z, Xie H, Su W, Wang H, Wang D, et al. The Rise in Norovirus-Related
364		Acute Gastroenteritis During the Fight Against the COVID-19 Pandemic in Southern
365		China. Front Public Heal. 2022;9(January):1–7.
366	13.	Zhang W, Wu Y, Wen B, Zhang Y, Wang Y, Yin W, et al. Non-pharmaceutical
367		interventions for COVID-19 reduced the incidence of infectious diseases: a controlled
368		interrupted time-series study. Infect Dis Poverty [Internet]. 2023;12(1):15. Available
369		from: https://doi.org/10.1186/s40249-023-01066-3
370	14.	Agoti CN, Curran MD, Murunga N, Ngari M, Muthumbi E, Lambisia AW, et al.
371		Differences in epidemiology of enteropathogens in children pre- and post-rotavirus
372		vaccine introduction in Kilifi, coastal Kenya. Gut Pathog [Internet]. 2022 Dec
373		1;14(1):32. Available from:
374		https://gutpathogens.biomedcentral.com/articles/10.1186/s13099-022-00506-z
375	15.	Lambisia AW. Comparison of the Diagnostic Performance of TaqMan Array Cards,
376		Enzyme Immunoassay, Real-Time PCR and Next Generation Sequencing in
377		Investigation of Five Common Diarrhoea-Associated Enteric Viruses in Kilifi, Kenya
378		[Internet]. JKUAT-COHES; 2021. Available from:
379		http://ir.jkuat.ac.ke/handle/123456789/5621
380	16.	Lambisia AW, Onchaga S, Murunga N, Lewa CS, Nyanjom SG, Agoti CN.
381		Epidemiological Trends of Five Common Diarrhea-Associated Enteric Viruses Pre- and
382		Post-Rotavirus Vaccine Introduction in Coastal Kenya. Pathogens [Internet]. 2020 Aug
383		15;9(8):660. Available from: https://www.mdpi.com/2076-0817/9/8/660

- 384 17. Nokes DJ, Abwao J, Pamba A, Peenze I, Dewar J, Maghenda JK, et al. Incidence and
- 385 Clinical Characteristics of Group A Rotavirus Infections among Children Admitted to
- 386 Hospital in Kilifi, Kenya. PLOS Med [Internet]. 2008 Jul 22;5(7):e153. Available from:
- 387 https://doi.org/10.1371/journal.pmed.0050153
- 18. Lambisia AW, Makori TO, Mutunga M, Cheruiyot R, Murunga N, Quick J, et al.
- 389 Genomic epidemiology of human adenovirus F40 and F41 in coastal Kenya: A
- 390 retrospective hospital-based surveillance study (2013-2022). Virus Evol.
- 391 2023;9(1):vead023.
- 392 19. Makori TO, Bargul JL, Lambisia AW, Mwanga MJ, Murunga N, de Laurent ZR, et al.
- 393 Genomic epidemiology of the rotavirus G2P[4] strains in coastal Kenya pre- and post-
- 394 rotavirus vaccine introduction, 2012–8. Virus Evol [Internet]. 2023 Jan
- 395 1;9(1):vead025. Available from: https://doi.org/10.1093/ve/vead025
- 396 20. Vennema H, Kroneman A. Rotavirus A Genotyping Tool [Internet]. [cited 2022 Apr
- 397 15]. Available from: https://www.rivm.nl/mpf/typingtool/rotavirusa/
- 398 21. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus
 399 Pandemic (COVID-19). Our World Data. 2020;
- 400 22. Brand SPC, Ojal J, Aziza R, Were V, Okiro EA, Kombe IK, et al. COVID-19 transmission
- 401 dynamics underlying epidemic waves in Kenya. Science (80-) [Internet]. 2021 Nov
- 402 19;374(6570):989–94. Available from:
- 403 https://www.science.org/doi/10.1126/science.abk0414
- 404 23. Lewis K. Vesikari Clinical Severity Scoring System Manual. Path [Internet].
- 405 2011;(May):1–50. Available from:
- 406 https://www.path.org/publications/files/VAD_vesikari_scoring_manual.pdf
- 407 24. Health M of. First case of coronavirus disease confirmed in Kenya. Press Release.
 408 2020;1–3.
- 409 25. Standard. Newborns at risk as shortage of the rotavirus vaccine is felt in various
- 410 clinics [Internet]. [cited 2023 Jun 2]. Available from:
- 411 https://www.standardmedia.co.ke/health/health-
- 412 science/article/2001448711/newborns-at-risk-as-shortage-of-the-rotavirus-vaccine-
- 413 is-felt-in-various-clinics
- 414 26. Amit LN, John JL, Mori D, Chin AZ, Mosiun AK, Ahmed K. Increase in rotavirus
- 415 prevalence with the emergence of genotype G9P[8] in replacement of genotype

- 416 G12P[6] in Sabah, Malaysia. Arch Virol [Internet]. 2023;168(6):173. Available from:
- 417 https://doi.org/10.1007/s00705-023-05803-9
- 418 27. Zhang SX, Zhou YM, Xu W, Tian LG, Chen JX, Chen SH, et al. Impact of co-infections
- 419 with enteric pathogens on children suffering from acute diarrhea in southwest China.
- 420 Infect Dis Poverty [Internet]. 2016 Dec 27;5(1):64. Available from:
- 421 http://idpjournal.biomedcentral.com/articles/10.1186/s40249-016-0157-2
- 422